| Project/Area Number |
17H06915
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
Toyota Yuka 香川大学, 医学部, 協力研究員 (00801565)
|
|---|
| Research Collaborator |
Masaki Tutomu
|
|---|
| Project Period (FY) |
2017-08-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 肝細胞癌 / 降圧薬テルミサルタン / テルミサルタン / 非ウイルス性肝細胞癌 / ARB / microRNA |
|---|
| Outline of Final Research Achievements |
In 3 types (HLE, HLF, HepG2) of HCC cultured cell lines,telmisartan showed cell growth inhibitory effect, and 2 types (HuH-7, PLC / PRF / 5)were not delected anti-tumor effect.G1 arrest was observed due to the reduction in the expression of cyclinD1, Cdk4 and cyclinE induced from G1 to S phase of the cell cycle by the addition of telmisartan. Increased expression of phospho-p53 (Ser392) and decreased expression of survivin, increased degradation product of CCK-18 were detected, and induction of apoptosis were also observed.
|
| Academic Significance and Societal Importance of the Research Achievements |
降圧薬telmisartanはいくつかのHCC細胞株でmiRNAを介したG1アレストおよびアポトーシスの誘導を起こし、抗腫瘍効果を併せ持つ薬剤と考えられる。本研究は、今後高血圧や糖尿病性腎症を有するHCC患者にどの降圧薬を選択するかの１つの指針となる。
|
